Latest Conference Articles

Rajesh Pahwa, MD: Advantages of Levodopa-Carbidopa Intestinal Gel

Rajesh Pahwa, MD: Advantages of Levodopa-Carbidopa Intestinal Gel

September 29th 2020

MDS

The director of the Parkinson’s Foundation Center for Excellence at University of Kansas Medical Center detailed the pros and cons of levodopa-carbidopa intestinal gel.

Satralizumab Benefits Relapse Risk Across NMOSD Treatment Spectrum

Satralizumab Benefits Relapse Risk Across NMOSD Treatment Spectrum

September 29th 2020

ECTRIMS

The medical director manager of neuroscience at Genentech offered her perspective on the mountain of data presented at MS Virtual 2020 on the recently approved NMOSD treatment.

Ponesimod Shows Safe Cardiac Profile in MS

Ponesimod Shows Safe Cardiac Profile in MS

September 28th 2020

ECTRIMS

Researchers concluded that uptitration of ponesimod was not associated with clinically significant bradyarrhythmia events; none were serious or lead to discontinuation.

Stephen L. Hauser, MD: Fenebrutinib and BTK Inhibiton in Progressive MS

Stephen L. Hauser, MD: Fenebrutinib and BTK Inhibiton in Progressive MS

September 26th 2020

ECTRIMS

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Low-Dose Rituximab Safe, as Effective as High Dose in MS

Low-Dose Rituximab Safe, as Effective as High Dose in MS

September 24th 2020

ECTRIMS

In the third year of treatment, both dose cohorts did not experience any contrast-enhancing lesions, and only a small population in the Barcelona center showed new T2 lesions.

Ocrelizumab Shows Range of Benefits for Spectrum of Patients With Multiple Sclerosis

Ocrelizumab Shows Range of Benefits for Spectrum of Patients With Multiple Sclerosis

September 24th 2020

ECTRIMS

The medical director manager of neuroscience at Genentech discussed the swath of data presented on the humanized anti-CD20 monoclonal antibody at MS Virtual.

Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach

Early Intensive MS Treatment Yields Better Outcomes Than Escalation Approach

September 23rd 2020

ECTRIMS

Early intensive treatment was more effective in controlling disability progression over time compared with an escalation therapy approach.

Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS

Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS

September 23rd 2020

ECTRIMS

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Fatigue Plays a Key Factor in Multiple Sclerosis Daily Functioning

Fatigue Plays a Key Factor in Multiple Sclerosis Daily Functioning

September 23rd 2020

ECTRIMS

Patients with lower levels of disability tended to report fatigue as the most impactful symptom in daily life.

Luc Truyen, MD, PhD: Advantages of Ponesimod as an S1P Modulator

Luc Truyen, MD, PhD: Advantages of Ponesimod as an S1P Modulator

September 22nd 2020

ECTRIMS

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed what makes ponesimod different from other currently FDA-approved treatments.